The WIN symposium 2019

Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) with PD-L1 advanced NSCLC

Using CT imaging to find radiomic signatures in surgically resected NSCLC

The role of afatinib in patients with EGFR NSCLC

Biomarkers of systemic inflammation linked to reduced clinical activity of atezolizumab monotherapy in metastatic TNBC

ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory acute myeloid leukaemia

Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer

Talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer

Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas

TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI

Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies

Combining the SLP vaccine with chemo-immunotherapy in order to increase the HPV-specific T-cell response in cervical cancer